Number 75

Old, young – does it matter?

Editorial 31 October 2016 1

Not so long ago, research protocols excluded older cancer patients based on chronologic age. Now they exclude patients with comorbidities, and as most older patients suffer additional ailments, they do not fit the protocols. But [more]

... [ more ]

Geriatric oncology: personalised medicine when you are old

Cover Story, Featured 31 October 2016 0

For most of us, sooner or later, old age will bring frailty and chronic health conditions, making the task of living the life we wish progressively harder. We will want oncologists who know what different [more]

... [ more ]

Active surveillance: the search for greater certainty

Cutting Edge, Featured 31 October 2016 0

Delaying treatment for a curable prostate cancer is an increasingly popular option among men with low risk tumours. Simon Crompton looks at efforts to learn more about who benefits and how to avoid delaying too [more]

... [ more ]

Silke Gillessen: tackling uncertainties and access in advanced prostate cancer

Featured, Profile 31 October 2016 1

Prioritising collaboration over self-interest is the way to learn about who gets the best from which treatments in the complex world of advanced prostate cancer. Silke Gillessen talked to Simon Crompton about how she is [more]

... [ more ]

Why most clinical research is not useful

Highlight, Spotlight on 31 October 2016 0

It makes no sense to perform clinical research that has no relevance to patient care, so why do we do it, and how can we stop? John Ioannidis ponders the problem and offers some suggestions. [more]

... [ more ]

Primary therapy of early hepatobiliary and pancreatic cancers: a review of the latest evidence

Featured, Grandround 31 October 2016 0

The state of the art on the diagnosis and management of cancer of the pancreas and hepatobiliary system was the focus of the 3rd St Gallen Gastrointestinal Cancer Conference, held earlier this year under the [more]

... [ more ]

TURNING POINT – “The panel recommends that bisphosphonates are considered as part of the adjuvant breast cancer treatment in postmenopausal women…”

Highlight, Spotlight on 31 October 2016 0

P Hadji, R E. Coleman, C Wilson et al. (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016, 27:379–90 Bisphosphonates should be considered as part [more]

... [ more ]

When your time is up. Conversations about dying from cancer

Focus 31 October 2016 1

Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a [more]

... [ more ]

Can advanced-stage ovarian cancer be cured?

Impact Factor 31 October 2016 0

Treatment of advanced-stage ovarian cancer should comprise optimal debulking surgery followed by adjuvant intraperitoneal chemotherapy. Steven Narod, from Women’s College Research Institute, Toronto, Canada, argues that widespread adoption of this model would increase cure rates [more]

... [ more ]

POLICY – Getting cancer onto the global development agenda – UICC and the NCD Alliance

Spotlight on 31 October 2016 1

Despite a rapid rise in cancer cases in low- and middle-income countries, many governments have been disastrously slow to turn their attention to planning and implementing cancer services, thanks in no small part to the [more]

... [ more ]